391 Results for "

ATP binding

" in MedChemExpress (MCE) Product Catalog:
Products (391)

391 Results for "ATP binding" in MCE Product Catalog:

135
Imatinib
Imatinib
0 Images
135 Publications Verification
Cat. No.: HY-15463
CAS No.: 152459-95-5
Purity:  99.95%
Synonyms: STI571; CGP-57148B
Target:  

Bcr-Abl PDGFR c-Kit SARS-CoV Autophagy

Research Areas:  

Cancer

Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively . Imatinib also is an inhibitor of SARS-CoV and MERS-CoV .
loading...
    loading...
View All Sizes
59
Sapanisertib
Sapanisertib
0 Images
59 Cited Publications
Cat. No.: HY-13328
CAS No.: 1224844-38-5
Purity:  99.63%
Synonyms: INK-128; MLN0128; TAK-228
Target:  

mTOR Apoptosis Akt ERK CDK Ribosomal S6 Kinase (RSK) Collagen HIF/HIF Prolyl-Hydroxylase Wnt

Research Areas:  

Cardiovascular Disease Inflammation/Immunology Cancer

Sapanisertib (INK-128; MLN0128; TAK-228) is an orally active dual mTORC1/mTORC2 inhibitor. Sapanisertib directly and simultaneously inhibits mTORC1/2 activity through competitive binding with ATP, thereby comprehensively blocking downstream processes such as protein and lipid synthesis and cytoskeletal reorganization, consequently suppressing tumor cell proliferation and promoting apoptosis. Sapanisertib is applicable to research on melanoma, ovarian cancer, pulmonary fibrosis, and hematological malignancies .
loading...
    loading...
View All Sizes
55
Ko 143
Ko 143
0 Images
55 Cited Publications
Cat. No.: HY-10010
CAS No.: 461054-93-3
Purity:  99.97%
Target:  

BCRP

Research Areas:  

Cancer

Ko 143 is a potent and selective ATP-binding cassette subfamily G member 2 (ABCG2/BCRP) inhibitor. Ko 143 displays >200-fold selectivity over P-gp and MRP-1 transporters .
loading...
    loading...
View All Sizes
52
CY-09
CY-09
0 Images
52 Cited Publications
Cat. No.: HY-103666
CAS No.: 1073612-91-5
Purity:  99.58%
Target:  

NOD-like Receptor (NLR)

Research Areas:  

Inflammation/Immunology

CY-09 is a selective and direct NLRP3 inhibitor. CY-09 directly binds to the ATP-binding motif of NLRP3 NACHT domain and inhibits NLRP3 ATPase activity, resulting in the suppression of NLRP3 inflammasome assembly and activation .
loading...
    loading...
View All Sizes
40
R406
R406
0 Images
40 Cited Publications
Cat. No.: HY-12067
CAS No.: 841290-81-1
Purity:  96.70%
Target:  

Syk FLT3 Apoptosis

Research Areas:  

Inflammation/Immunology Cancer

R406 is an orally available and competitive Syk/FLT3 inhibitor for ATP binding with a Ki of 30 nM, potently inhibits Syk kinase activity in vitro with an IC50 of 41 nM, measured at an ATP concentration corresponding to its Km value. R406 reduces immune complex-mediated inflammation . R406 also inhibits Lyn (IC50=63 nM) and Lck (IC50=37 nM) .
loading...
    loading...
View All Sizes
40
R406 free base
R406 free base
0 Images
40 Cited Publications
Cat. No.: HY-11108
CAS No.: 841290-80-0
Purity:  99.80%
Target:  

Syk FLT3 Apoptosis

Research Areas:  

Inflammation/Immunology Cancer

R406 free base is an orally available and competitive Syk/FLT3 inhibitor for ATP binding with a Ki of 30 nM, potently inhibits Syk kinase activity in vitro with an IC50 of 41 nM, measured at an ATP concentration corresponding to its Km value. R406 free base reduces immune complex-mediated inflammation . R406 free base also inhibits Lyn (IC50=63 nM) and Lck (IC50=37 nM) .
loading...
    loading...
View All Sizes
37
Acalabrutinib
Acalabrutinib
0 Images
37 Cited Publications
Cat. No.: HY-17600
CAS No.: 1420477-60-6
Synonyms: Calquence; ACP-196
Target:  

Btk

Research Areas:  

Infection Inflammation/Immunology Cancer

Acalabrutinib (ACP-196) is an orally active, irreversible, and highly selective second-generation BTK inhibitor. Acalabrutinib binds covalently to Cys481 in the ATP-binding pocket of BTK. Acalabrutinib demonstrates potent on-target effects and efficacy in mouse models of chronic lymphocytic leukemia (CLL). Acalabrutinib can be used for CLL research . Acalabrutinib is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
loading...
    loading...
View All Sizes
33
Takinib
Takinib
0 Images
33 Cited Publications
Cat. No.: HY-103490
CAS No.: 1111556-37-6
Purity:  99.41%
Synonyms: EDHS-206
Target:  

MAP3K Apoptosis

Research Areas:  

Infection Inflammation/Immunology Cancer

Takinib (EDHS-206) is an orally active and selective TAK1 inhibitor (IC50=9.5 nM), more than 1.5 log more potent than the second and third ranked targets, IRAK4 (120 nM) and IRAK1 (390 nM), respectively. Takinib is an inhibitor of autophosphorylated TAK1 that non-competitively binds within the ATP binding pocket. Takinib induces apoptosis following TNFα stimulation in cell models of rheumatoid arthritis and metastatic breast cancer. Takinib is also a P. falciparum protein kinase 9 (PfPK9) inhibitor (KD(app) of 0.46 μM) .
loading...
    loading...
View All Sizes
16
Acacetin
Acacetin
0 Images
16 Cited Publications
Cat. No.: HY-N0451
CAS No.: 480-44-4
Synonyms: 5,7-Dihydroxy-4'-methoxyflavone
Category:  

Neurological Disease Anti-aging Flavones 500 - Internal Server Error | MedChemExpress

Oops!

Sorry, Something went wrong on our server.
Our team has been notified and is working to fix the issue.